Merck KGaA will not take zerlasiran, the Lp(a)-lowering drug it is set to gain by buying Silence Therapeutics, into late-stage trials. Its healthcare chief told investors on 12 November 2026 that the company would not pursue the Lp(a) project, days after full results showed Novartis's rival drug pelacarsen did not cut heart attacks or strokes.
The German group agreed on 19 October to buy London-based Silence for $20.00 per American Depositary Share in cash. The main prize was always divesiran, a drug for the rare blood disorder polycythaemia vera. The zerlasiran decision leaves divesiran as the clear focus of the $1.3 billion deal.
- The trigger: pelacarsen cut Lp(a) by 78% in the 8,323-patient Lp(a)HORIZON trial but did not reduce major cardiovascular events.
- The deal: about $1.3 billion in equity value, expected to close in the first quarter of 2027.
- Still running: Amgen's olpasiran and Lilly's lepodisiran are in Phase 3 outcomes trials.
- Irish link: Merck KGaA has about 750 staff in Ireland, mainly in Cork. None of the Lp(a) trials named here lists an Irish site.
What did Merck KGaA decide?
On Merck KGaA's third-quarter results call on 12 November, an analyst asked about Silence's second drug, zerlasiran, in light of the pelacarsen data. According to a transcript of the call, Danny Bar-Zohar, chief executive of Merck KGaA's healthcare business, called the Novartis results disappointing and said the company would not continue the Lp(a) project. Bloomberg and Quartz reported this as a decision not to advance zerlasiran into late-stage trials.
Zerlasiran is a small interfering RNA (siRNA) medicine designed to lower lipoprotein(a), or Lp(a). Its completed Phase 2 trial (NCT05537571) enrolled 180 people. In March 2026 Silence called it "Phase 3 ready" and said it was seeking a partner.
Why did the pelacarsen result matter?
Lp(a)HORIZON (NCT04023552) tested whether lowering Lp(a) with pelacarsen prevents heart attacks and strokes. It enrolled 8,323 adults with established cardiovascular disease and high Lp(a) between 2019 and 2026. Novartis, which licensed pelacarsen from Ionis, said on 4 September that the trial missed its primary endpoint.
Full results were presented at the American Heart Association's Scientific Sessions on 7 November and published in the New England Journal of Medicine. According to the AHA, pelacarsen lowered Lp(a) by 78%, but the time to a first heart attack, stroke, urgent artery procedure or cardiovascular death did not differ from placebo. About 21% of patients on the drug stopped treatment because of side effects, against more than 7% on placebo.
Bloomberg reported the same day that Novartis will stop developing pelacarsen for atherosclerotic cardiovascular disease, keeping one trial in a heart valve disease. Because zerlasiran also works by lowering Lp(a), the result bears directly on it.
What is Merck KGaA buying Silence for?
Divesiran is an siRNA drug for polycythaemia vera, a rare blood cancer in which the body makes too many red blood cells. In August 2026 Silence reported that, in 48 patients who depended on regular blood removal, 88% of those on divesiran responded over 36 weeks, against 19% on placebo. Silence expects a Phase 3 trial to start in the first half of 2027.
The $1.3 billion price is a 130% premium to Silence's share price on 16 October. The deal is a UK scheme of arrangement, so it needs approval from Silence shareholders, the High Court of England and Wales and regulators. On the call, Group CEO Kai Beckmann repeated that closing is expected in the first quarter of 2027.
Are other Lp(a) drugs still in trials?
Yes. ClinicalTrials.gov shows two large outcomes trials still under way:
- Amgen, olpasiran: OCEAN(a)-Outcomes (NCT05581303) has enrolled 7,297 patients and is no longer recruiting; primary completion is estimated for March 2028. A second trial, OCEAN(a)-PreEvent (NCT07136012), is recruiting people who have not yet had a cardiovascular event.
- Eli Lilly, lepodisiran: ACCLAIM-Lp(a) (NCT06292013) lists an estimated 17,300 participants, including people at risk of a first event, with primary completion estimated for March 2029.
HORIZON enrolled only people who already had cardiovascular disease, so these trials test different drugs and, in part, different patients.
What is the Irish angle?
Merck KGaA employed about 753 people in Ireland at the end of 2024, according to the Irish Times, in its life science business rather than the healthcare unit buying Silence. Its main Irish site, Carrigtwohill in Co Cork, makes membranes used in drug manufacturing, and a €150 million filtration plant opened at Blarney Business Park in September 2025. In October 2025 the company said it plans to end operations at its Arklow, Co Wicklow, plant, which makes ingredients for medicines, by the end of 2028.
Novartis has operated in Ireland since the 1950s. The ClinicalTrials.gov records for HORIZON, zerlasiran's Phase 2 trial, OCEAN(a)-Outcomes and ACCLAIM-Lp(a) list no Irish sites. More is on our Merck KGaA and Novartis Ireland pages and our pelacarsen, olpasiran and lepodisiran trial pages.
What is Lp(a), and does testing still matter?
Lp(a) is a cholesterol-carrying particle in the blood. The European Society of Cardiology says its level is predominantly determined by genetics. The ESC's 2025 guideline update advises doctors to consider measuring Lp(a) at least once in each adult's lifetime, and treats levels above 50 mg/dL (105 nmol/L) as a factor that raises cardiovascular risk. Steven Nissen, who led HORIZON, said after the results: "Measuring Lp(a) is still absolutely worthwhile."
Frequently asked questions
Is zerlasiran approved?
No. Zerlasiran, pelacarsen, olpasiran and lepodisiran are all investigational and are not approved for use in Ireland or the EU.
Were Irish patients in these trials?
The ClinicalTrials.gov records list no Irish sites. This article is not medical advice; anyone concerned about their cholesterol or Lp(a) should speak to their GP.
Outlook
The next milestones are the Silence shareholder vote and court hearing, the start of a divesiran Phase 3 trial, and the Amgen and Lilly outcomes results expected from 2028. Priya Life Science will report on any decision about zerlasiran's future and on the Irish sites of both companies.
Sources
- Silence Therapeutics, Merck KGaA to acquire Silence Therapeutics (Form 8-K, Exhibit 99.1), 19 October 2026
- Investing.com, Earnings call transcript: Merck KGaA Q3 2026, 12 November 2026
- Silence Therapeutics, Positive topline results from Phase 2 SANRECO trial of divesiran (Form 8-K, Exhibit 99.1), 10 August 2026
- Silence Therapeutics, Fourth quarter and full year 2025 financial results, 5 March 2026
- Novartis, Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen, 4 September 2026
- American Heart Association, Lp(a) HORIZON trial: Lp(a) fell by 78%, but cardiovascular outcomes unexpectedly neutral, 7 November 2026
- New England Journal of Medicine, Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a), 7 November 2026
- Bloomberg via Swissinfo, Novartis abandons heart drug after surprising failure in key study, 7 November 2026
- ClinicalTrials.gov records: NCT04023552 (Lp(a)HORIZON), NCT05537571 (zerlasiran Phase 2), NCT05581303 (OCEAN(a)-Outcomes), NCT07136012 (OCEAN(a)-PreEvent) and NCT06292013 (ACCLAIM-Lp(a)), accessed 13 November 2026
- European Society of Cardiology, What is new in the 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, 2 December 2025
- Irish Times, Merck to close Arklow plant, 22 October 2025
- Irish Examiner, €150m filtration manufacturing facility opens in Blarney, 18 September 2025, and Merck to expand Cork operations, 23 May 2022
- Novartis Ireland, About Novartis Ireland, accessed 13 November 2026
Cover image: AI-generated illustration of blood sample tubes in a hospital laboratory. It does not show zerlasiran, pelacarsen, a trial site or real people.